SQZ Biotechnologies gets FDA fast-track designation for SQZ-PBMC-HPV 04/27 SQZ SQZ Biotechnologies "announced that the FDA has granted Fast Track Designation for the company's lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. Data presented at the ESMO Immuno-Oncology Congress 2021 has shown that the company's lead APC cell therapy candidate induced radiographic, symptomatic and immune response as monotherapy in a post-checkpoint HPV16+ solid tumor patient. The company continues to enroll patients in its highest dose monotherapy cohort and is simultaneously enrolling patients for combination therapy in the company's Phase 1/2 SQZ-PBMC-HPV-101 clinical trial."
SQZ Biotechnologies Company (SQZ)
3.3500-0.0300(-0.89%)
At close: May 24 04:00PM EDT
3.5800+0.23(+6.87%)<------------
Pre-Market:07:37AM EDT